. | Resectable . | Borderline-resectable . | Unresectable . |
---|---|---|---|
(n = 34) | (n = 35) | (n = 35) | |
Age | |||
Median/range (years) | 70/56–84 | 67/48–84 | 67/51–82 |
Sex | |||
Male/female | 28/6 | 29/6 | 31/4 |
Performance status | |||
0/1/2/3 | 9/16/8/1 | 8/25/2/0 | 7/21/5/2 |
T-Factora | |||
1/2/3/4 | 14/11/9/0 | 0/2/18/15 | 3/3/1/28 |
N-Factor | |||
0/1/2/3 | 21/6/6/1 | 6/11/12/6 | 2/11/9/13 |
Stage | |||
1/2/3/4 | 18/6/10/0 | 0/1/28/6 | 0/0/19/16 |
Operabilityb | |||
Operable/inoperable | 22/12 | 33/2 | NAe |
Chemotherapy | |||
PF-q4w/PF-low dosec | 22/12 | 11/24d | 10/25 |
. | Resectable . | Borderline-resectable . | Unresectable . |
---|---|---|---|
(n = 34) | (n = 35) | (n = 35) | |
Age | |||
Median/range (years) | 70/56–84 | 67/48–84 | 67/51–82 |
Sex | |||
Male/female | 28/6 | 29/6 | 31/4 |
Performance status | |||
0/1/2/3 | 9/16/8/1 | 8/25/2/0 | 7/21/5/2 |
T-Factora | |||
1/2/3/4 | 14/11/9/0 | 0/2/18/15 | 3/3/1/28 |
N-Factor | |||
0/1/2/3 | 21/6/6/1 | 6/11/12/6 | 2/11/9/13 |
Stage | |||
1/2/3/4 | 18/6/10/0 | 0/1/28/6 | 0/0/19/16 |
Operabilityb | |||
Operable/inoperable | 22/12 | 33/2 | NAe |
Chemotherapy | |||
PF-q4w/PF-low dosec | 22/12 | 11/24d | 10/25 |
aTwo T2 patients in borderline-resectable had large lymph node metasitasis with probable invasion to surrounding tissues and 7 T1–3 patients in unresectable had cervival or supraclavicular lymph node metastasis; bOperability was judged by surgeons according to patient’s medical condition including comorbidity. This does not mean resectability; cPF-q4w, 2 cycles of cisplatin and 5-fluorouracil every 4 weeks; PF-low dose, cisplatin and 5-fluorouracil 5 days a week for 20 days; dFifteen patients received definitive chemoradiotherapy due to poor response after induction chemoradiotherapy; eNA, not available/operability was not fully evaluated in unresectable patients.
. | Resectable . | Borderline-resectable . | Unresectable . |
---|---|---|---|
(n = 34) | (n = 35) | (n = 35) | |
Age | |||
Median/range (years) | 70/56–84 | 67/48–84 | 67/51–82 |
Sex | |||
Male/female | 28/6 | 29/6 | 31/4 |
Performance status | |||
0/1/2/3 | 9/16/8/1 | 8/25/2/0 | 7/21/5/2 |
T-Factora | |||
1/2/3/4 | 14/11/9/0 | 0/2/18/15 | 3/3/1/28 |
N-Factor | |||
0/1/2/3 | 21/6/6/1 | 6/11/12/6 | 2/11/9/13 |
Stage | |||
1/2/3/4 | 18/6/10/0 | 0/1/28/6 | 0/0/19/16 |
Operabilityb | |||
Operable/inoperable | 22/12 | 33/2 | NAe |
Chemotherapy | |||
PF-q4w/PF-low dosec | 22/12 | 11/24d | 10/25 |
. | Resectable . | Borderline-resectable . | Unresectable . |
---|---|---|---|
(n = 34) | (n = 35) | (n = 35) | |
Age | |||
Median/range (years) | 70/56–84 | 67/48–84 | 67/51–82 |
Sex | |||
Male/female | 28/6 | 29/6 | 31/4 |
Performance status | |||
0/1/2/3 | 9/16/8/1 | 8/25/2/0 | 7/21/5/2 |
T-Factora | |||
1/2/3/4 | 14/11/9/0 | 0/2/18/15 | 3/3/1/28 |
N-Factor | |||
0/1/2/3 | 21/6/6/1 | 6/11/12/6 | 2/11/9/13 |
Stage | |||
1/2/3/4 | 18/6/10/0 | 0/1/28/6 | 0/0/19/16 |
Operabilityb | |||
Operable/inoperable | 22/12 | 33/2 | NAe |
Chemotherapy | |||
PF-q4w/PF-low dosec | 22/12 | 11/24d | 10/25 |
aTwo T2 patients in borderline-resectable had large lymph node metasitasis with probable invasion to surrounding tissues and 7 T1–3 patients in unresectable had cervival or supraclavicular lymph node metastasis; bOperability was judged by surgeons according to patient’s medical condition including comorbidity. This does not mean resectability; cPF-q4w, 2 cycles of cisplatin and 5-fluorouracil every 4 weeks; PF-low dose, cisplatin and 5-fluorouracil 5 days a week for 20 days; dFifteen patients received definitive chemoradiotherapy due to poor response after induction chemoradiotherapy; eNA, not available/operability was not fully evaluated in unresectable patients.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.